TCL Archive Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate March 25, 2011
TCL Archive In Brief: Construction Grant Application Deadline for 75-25% Funding Oct. 1; Fordham Quits April 29, 1977
TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
TCL Archive Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer July 11, 2014
